157 related articles for article (PubMed ID: 30880071)
1. Surufatinib in neuroendocrine tumours.
Das M
Lancet Oncol; 2019 Apr; 20(4):e196. PubMed ID: 30880071
[No Abstract] [Full Text] [Related]
2. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
[TBL] [Abstract][Full Text] [Related]
3. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844
[TBL] [Abstract][Full Text] [Related]
4. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
[TBL] [Abstract][Full Text] [Related]
5. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.
Grillo F; Florio T; Ferraù F; Kara E; Fanciulli G; Faggiano A; Colao A;
Endocr Relat Cancer; 2018 Sep; 25(9):R453-R466. PubMed ID: 29769293
[TBL] [Abstract][Full Text] [Related]
6. Surufatinib: First Approval.
Syed YY
Drugs; 2021 Apr; 81(6):727-732. PubMed ID: 33788183
[TBL] [Abstract][Full Text] [Related]
7. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
Ahlman H; Nilsson O; Nilsson B
Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
[No Abstract] [Full Text] [Related]
8. Surufatinib - a novel oral agent for neuroendocrine tumours.
Koumarianou A; Kaltsas G
Nat Rev Endocrinol; 2021 Jan; 17(1):9-10. PubMed ID: 33128026
[No Abstract] [Full Text] [Related]
9. Promising advances in the treatment of malignant pancreatic endocrine tumors.
Jensen RT; Delle Fave G
N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
[No Abstract] [Full Text] [Related]
10. Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
Furman RR; Luan Y; Bilotti E; Graef T
Leuk Lymphoma; 2017 Jun; 58(6):1502-1505. PubMed ID: 27784188
[No Abstract] [Full Text] [Related]
11. CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas.
Kuravi S; Parrott E; Mudduluru G; Cheng J; Ganguly S; Saunthararajah Y; Jensen RA; Blagg BS; McGuirk JP; Balusu R
Blood Cancer J; 2019 Jan; 9(2):14. PubMed ID: 30696805
[No Abstract] [Full Text] [Related]
12. Chronic myeloid leukemia: Second-line drugs of choice.
Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R
Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.
Valle JW; Borbath I; Rosbrook B; Fernandez K; Raymond E
Future Oncol; 2019 Apr; 15(11):1219-1230. PubMed ID: 30701988
[TBL] [Abstract][Full Text] [Related]
14. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.
Lu X; Yan S; Koral KA; Chen Z
Expert Rev Anticancer Ther; 2021 Sep; 21(9):917-926. PubMed ID: 34142932
[No Abstract] [Full Text] [Related]
15. Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):11-3. PubMed ID: 27168106
[No Abstract] [Full Text] [Related]
16. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Breccia M; Colafigli G; Molica M; Alimena G
Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
[TBL] [Abstract][Full Text] [Related]
17. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
Mahon FX
Clin Adv Hematol Oncol; 2019 Feb; 17(2):101-103. PubMed ID: 30845112
[No Abstract] [Full Text] [Related]
18. Neuroendocrine tumors: nursing implications for oral targeted agents and patient management: Part II.
Jacobs C
Clin J Oncol Nurs; 2009 Apr; 13(2):149-53. PubMed ID: 19349261
[No Abstract] [Full Text] [Related]
19. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
[No Abstract] [Full Text] [Related]
20. Pulmonary toxicities of tyrosine kinase inhibitors.
Peerzada MM; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
